Litafd, a Litaf domain-containing protein, plays a pivotal role in cellular processes by participating in transcriptional regulation. Functionally, Litafd is involved in orchestrating responses to various stimuli, contributing to diverse cellular functions. Activation of Litafd involves a sophisticated interplay of signaling pathways, both direct and indirect, which modulate its expression and impact downstream cellular responses. Direct activators, such as Forskolin, PMA, and IL-1β, directly engage with Litafd, inducing its expression through pathways like NF-κB or MAPK. Indirect activators, including LPS, EGF, and TGF-β, influence Litafd expression through complex signaling cascades, such as TLR4/NF-κB or MAPK/ERK. These pathways converge to regulate the transcriptional machinery associated with Litafd, leading to its activation.
The NF-κB pathway emerges as a central player in Litafd activation, with various stimuli, such as TNF-α, IL-1β, and LPS, converging on this pathway to influence Litafd expression. Additionally, other pathways like JAK/STAT and MAPK/ERK contribute to the modulation of Litafd, providing a multifaceted regulatory network. The intricate interplay of these pathways, influenced by different chemical activators, highlights the complexity of Litafd activation in cellular contexts. Understanding these activation mechanisms provides insights into the broader regulatory landscape of Litafd and its role in cellular responses to external stimuli.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
Phorbol 12-myristate 13-acetate (PMA), a direct activator, induces Litafd activation through protein kinase C (PKC). PMA activates PKC, leading to downstream phosphorylation events that enhance Litafd expression by promoting its transactivation. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
PGE2, an indirect activator, enhances Litafd expression through the EP2 receptor and cAMP signaling. PGE2 binding to EP2 activates adenylyl cyclase, increasing cAMP levels. Elevated cAMP influences the NF-κB pathway, leading to enhanced Litafd gene transcription. | ||||||
Lipopolysaccharide, E. coli O55:B5 | 93572-42-0 | sc-221855 sc-221855A sc-221855B sc-221855C | 10 mg 25 mg 100 mg 500 mg | $98.00 $171.00 $425.00 $1560.00 | 12 | |
LPS, an indirect activator, stimulates Litafd expression through the TLR4/NF-κB pathway. LPS binding to TLR4 triggers downstream signaling cascades, leading to the activation of NF-κB and subsequent enhancement of Litafd gene transcription. | ||||||
Lysophosphatidic Acid | 325465-93-8 | sc-201053 sc-201053A | 5 mg 25 mg | $98.00 $341.00 | 50 | |
LPA, a direct activator, enhances Litafd expression through GPCR-mediated signaling. LPA binding to its receptor activates intracellular signaling cascades that contribute to the modulation of transcription factors involved in Litafd gene transcription. The resulting cellular responses contribute to increased Litafd expression. | ||||||